More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.60B
EPS
-2.68
P/E ratio
--
Price to sales
15.06
Dividend yield
--
Beta
0.511613
Previous close
$26.98
Today's open
$27.02
Day's range
$26.29 - $27.20
52 week range
$17.34 - $30.00
show more
CEO
Brian Webster
Employees
--
Headquarters
Kirkland, WA
Exchange
Nasdaq Global Select
Shares outstanding
59561795
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.
GlobeNewsWire • Oct 1, 2026

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon
Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by improved payer mix, scale, and supplier leverage, validating its unit economics story. Despite strong top-line momentum and raised FY27 guidance, profitability remains distant with a $44M net loss and $32M quarterly cash burn.
Seeking Alpha • Sep 16, 2026

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures falling around 200 points on Tuesday.
Benzinga • Sep 15, 2026

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Seeking Alpha • Sep 15, 2026

Kestra Medical Technologies Q1 Earnings Call Highlights
Kestra Medical Technologies NASDAQ: KMTS reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outlook to $141 million from a prior forecast of $137 million, representing expected growth of 48% over fiscal 2026.
MarketBeat • Sep 14, 2026

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.
GlobeNewsWire • Sep 14, 2026

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61.
Zacks Investment Research • Sep 14, 2026

Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) will release its first earnings report after the closing bell on Monday, Sept.
Benzinga • Sep 11, 2026

Kestra Names Daniel Finney Vice President of Research & Development
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company's executive leadership team.
GlobeNewsWire • Sep 10, 2026

Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for
Kestra Medical Technologies, Ltd. (KMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Zacks Investment Research • Sep 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kestra Medical Technologies Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.